Cardiac Troponin I (TNNI3) Monoclonal Antibody

Background
Troponin I (TnI), along with troponin T (TnT) and troponin C (TnC), is one of 3 subunits that form the troponin complex of the thin filaments of striated muscle. TnI is the inhibitory subunit; blocking actin-myosin interactions and thereby mediating striated muscle relaxation. The TnI subfamily contains three genes: TnI-skeletal-fast-twitch, TnI-skeletal-slow-twitch, and TnI-cardiac. This gene encodes the TnI-cardiac protein and is exclusively expressed in cardiac muscle tissues. Mutations in this gene cause familial hypertrophic cardiomyopathy type 7 (CMH7) and familial restrictive cardiomyopathy (RCM). Troponin I is useful in making a diagnosis of heart failure, and of ischemic heart disease. An elevated level of troponin is also now used as indicator of acute myocardial injury in patients hospitalized with moderate/severe Coronavirus Disease 2019 (COVID-19). Such elevation has also been associated with higher risk of mortality in cardiovascular disease patients hospitalized due to COVID-19.

Description
Cardiac Troponin I (TNNI3) Monoclonal Antibody. Unconjugated. Raised in: Rabbit.

Formulation
Buffer: PBS containing 50% glycerol and 0.05% BSA, preserved with proclin300 or sodium azide, pH 7.3.

Specificity
Mouse, Rat

Isotype
IgG

Uniprot ID
P19429

Purification
Affinity Purified

Immunogen
Recombinant protein (or fragment). Please contact EpigenTek for more information.

Storage
Store at -20°C. Avoid freeze / thaw cycles.

Alternative Names
CMH7; RCM1; cTnI; CMD2A; TNNC1; CMD1FF; Cardiac Troponin I (TNNI3)

Application
WB, IF-P, ELISA; Recommended dilution: WB, 1:1000 - 1:5000; IF-P, 1:100 - 1:500; ELISA, Recommended starting concentration is 1 µg/mL. Please optimize the concentration based on your specific assay requirements.